Khalid Al‐Shibli

4.2k total citations · 1 hit paper
44 papers, 3.2k citations indexed

About

Khalid Al‐Shibli is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Khalid Al‐Shibli has authored 44 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 19 papers in Molecular Biology and 15 papers in Cancer Research. Recurrent topics in Khalid Al‐Shibli's work include Cancer Immunotherapy and Biomarkers (10 papers), Cancer Cells and Metastasis (9 papers) and Immunotherapy and Immune Responses (8 papers). Khalid Al‐Shibli is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Cancer Cells and Metastasis (9 papers) and Immunotherapy and Immune Responses (8 papers). Khalid Al‐Shibli collaborates with scholars based in Norway, Singapore and Spain. Khalid Al‐Shibli's co-authors include Tom Dønnem, Roy M. Bremnes, Lill‐Tove Busund, Samer Al‐Saad, Sigve Andersen, Magnus Persson, Carlos Camps, Rafael Sirera, Helge Stenvold and Sveinung Wergeland Sørbye and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer.

In The Last Decade

Khalid Al‐Shibli

43 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer

2010 525 citations Roy M. Bremnes, Tom Dønnem et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Khalid Al‐Shibli Norway	28	1.8k	1.3k	979	916	810	44	3.2k
Sigve Andersen Norway	33	2.0k 1.1×	1.6k 1.3×	1.4k 1.4×	981 1.1×	1.2k 1.5×	80	3.9k
Samer Al‐Saad Norway	36	2.3k 1.3×	1.7k 1.4×	1.3k 1.4×	1.3k 1.4×	1.2k 1.5×	66	4.3k
Claire Bonneau France	21	1.9k 1.1×	1.2k 0.9×	904 0.9×	901 1.0×	450 0.6×	72	3.5k
Marleen Kok Netherlands	30	2.3k 1.3×	1.1k 0.9×	887 0.9×	953 1.0×	817 1.0×	90	3.6k
Masanori Oshi Japan	31	1.4k 0.8×	1.3k 1.0×	1.1k 1.1×	640 0.7×	961 1.2×	132	2.8k
Shijun Kang China	12	2.0k 1.1×	881 0.7×	552 0.6×	1.2k 1.3×	853 1.1×	22	3.0k
Jonathan J. Havel United States	13	1.9k 1.1×	825 0.6×	493 0.5×	1.1k 1.2×	683 0.8×	14	2.7k
Oscar Krijgsman Netherlands	27	1.4k 0.8×	1.4k 1.1×	757 0.8×	493 0.5×	426 0.5×	63	2.8k
Hee Jin Lee South Korea	33	1.6k 0.9×	1.3k 1.0×	1.0k 1.0×	817 0.9×	453 0.6×	116	3.3k

Countries citing papers authored by Khalid Al‐Shibli

Since Specialization

Citations

This map shows the geographic impact of Khalid Al‐Shibli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid Al‐Shibli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid Al‐Shibli more than expected).

Fields of papers citing papers by Khalid Al‐Shibli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khalid Al‐Shibli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid Al‐Shibli. The network helps show where Khalid Al‐Shibli may publish in the future.

Co-authorship network of co-authors of Khalid Al‐Shibli

This figure shows the co-authorship network connecting the top 25 collaborators of Khalid Al‐Shibli. A scholar is included among the top collaborators of Khalid Al‐Shibli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khalid Al‐Shibli. Khalid Al‐Shibli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Madsen, Martin Bruun, et al.. (2025). Hyperparathyroidism-Jaw Tumor Syndrome: A Case Diagnosed After the Removal of Multiple Ossifying Fibromas of the Jaws. JCEM Case Reports. 3(4). luaf049–luaf049.

Braaten, Tonje, et al.. (2019). Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study. Journal of Translational Medicine. 17(1). 334–334. 47 indexed citations

Sørbye, Sveinung Wergeland, et al.. (2017). Accuracy of cervical cytology: comparison of diagnoses of 100 Pap smears read by four pathologists at three hospitals in Norway. BMC Clinical Pathology. 17(1). 18–18. 54 indexed citations

Norum, Jan, et al.. (2017). Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis. ESMO Open. 2(3). e000222–e000222. 12 indexed citations

Dønnem, Tom, Sigurd M. Hald, Erna‐Elise Paulsen, et al.. (2015). Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(11). 2635–2643. 252 indexed citations

Andersen, Sigve, Samer Al‐Saad, Yury Kiselev, et al.. (2014). Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival. PLoS ONE. 9(9). e105038–e105038. 63 indexed citations

Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2013). Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas. BMC Clinical Pathology. 13(1). 9–9. 3 indexed citations

Dønnem, Tom, Christopher G. Fenton, Thomas Berg, et al.. (2012). MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer. PLoS ONE. 7(1). e29671–e29671. 91 indexed citations

Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2012). Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clinical Pathology. 12(1). 5–5. 28 indexed citations

10.

Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2012). Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clinical Pathology. 12(1). 7–7. 23 indexed citations

11.

Andersen, Sigve, Tom Dønnem, Samer Al‐Saad, et al.. (2011). Correlation and coexpression of HIFs and NOTCH markers in NSCLC.. PubMed. 31(5). 1603–6. 14 indexed citations

12.

Dønnem, Tom, Sigve Andersen, Samer Al‐Saad, et al.. (2011). Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size. Clinical Lung Cancer. 12(2). 106–115. 20 indexed citations

13.

Dønnem, Tom, Thomas Berg, Sveinung Wergeland Sørbye, et al.. (2011). Independent and tissue‐specific prognostic impact of miR‐126 in nonsmall cell lung cancer. Cancer. 117(14). 3193–3200. 62 indexed citations

14.

Dønnem, Tom, Thomas Berg, Sveinung Wergeland Sørbye, et al.. (2011). Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization. Journal of Translational Medicine. 9(1). 6–6. 96 indexed citations

15.

Bremnes, Roy M., Tom Dønnem, Samer Al‐Saad, et al.. (2010). The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(1). 209–217. 525 indexed citations breakdown →

16.

Al‐Shibli, Khalid, Samer Al‐Saad, Sigve Andersen, et al.. (2010). The prognostic value of intraepithelial and stromal CD3‐, CD117‐ and CD138‐positive cells in non‐small cell lung carcinoma. Apmis. 118(5). 371–382. 47 indexed citations

17.

Al‐Shibli, Khalid, Samer Al‐Saad, Tom Dønnem, et al.. (2009). The prognostic value of intraepithelial and stromal innate immune system cells in non‐small cell lung carcinoma. Histopathology. 55(3). 301–312. 86 indexed citations

18.

Dønnem, Tom, Khalid Al‐Shibli, Samer Al‐Saad, Lill‐Tove Busund, & Roy M. Bremnes. (2009). Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival. Journal of Thoracic Oncology. 4(5). 578–585. 64 indexed citations

19.

Dønnem, Tom, Samer Al‐Saad, Khalid Al‐Shibli, et al.. (2008). Prognostic Impact of Platelet-Derived Growth Factors in Non-small Cell Lung Cancer Tumor and Stromal Cells. Journal of Thoracic Oncology. 3(9). 963–970. 96 indexed citations

20.

Dønnem, Tom, Khalid Al‐Shibli, Samer Al‐Saad, et al.. (2008). VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: Inverse correlation between expression in tumor and stromal cells. Lung Cancer. 63(2). 277–283. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact